Research Topic

Tumor Microenvironment and Resistance to Current Therapies

About this Research Topic

The tumor microenvironment emerged as an essential target of cancer therapy. Henceforth,
beside tumor surgery, current therapeutic strategies reveal that harnessing cancer is beyond our focus on the biology of cancer cells. Interactions of cancer cells with different host cells, resident or recruited to tumor site are critical in fueling or inhibiting tumor progression. Several therapies targeting the host compartment of tumors have been designed and currently applied in the clinic. In addition to stroma-targeted therapies, novel strategies based on unleashing the immune response against tumor cells have been found to be successful in oncology for numerous cancers.

Currently, check point inhibitors, mostly for T cells, are considered as the most promising option for treating advanced and aggressive cancers. Other strategies targeting NK cells, myeloid suppressive cells and other immune cells are also emerging. However many patients remain resistant to the host targeting therapies, urging the development of biomarkers and novel therapeutic strategies, based on combining drugs that could counteract resistance.


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

The tumor microenvironment emerged as an essential target of cancer therapy. Henceforth,
beside tumor surgery, current therapeutic strategies reveal that harnessing cancer is beyond our focus on the biology of cancer cells. Interactions of cancer cells with different host cells, resident or recruited to tumor site are critical in fueling or inhibiting tumor progression. Several therapies targeting the host compartment of tumors have been designed and currently applied in the clinic. In addition to stroma-targeted therapies, novel strategies based on unleashing the immune response against tumor cells have been found to be successful in oncology for numerous cancers.

Currently, check point inhibitors, mostly for T cells, are considered as the most promising option for treating advanced and aggressive cancers. Other strategies targeting NK cells, myeloid suppressive cells and other immune cells are also emerging. However many patients remain resistant to the host targeting therapies, urging the development of biomarkers and novel therapeutic strategies, based on combining drugs that could counteract resistance.


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

27 December 2017 Abstract
13 June 2018 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

27 December 2017 Abstract
13 June 2018 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..

Comments

Loading..

Add a comment

Add comment
Back to top